A carregar...
Case report: use of lenzilumab and tocilizumab for the treatment of coronavirus disease 2019
Background: Coronavirus disease 2019 (COVID-19) is a novel disease associated with a cytokine-mediated, severe, acute respiratory syndrome. Tocilizumab and lenzilumab are recombinant monoclonal antibodies against IL-6 and granulocyte macrophage colony-stimulating factor, respectively, and have been...
Na minha lista:
| Publicado no: | Immunotherapy |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Future Medicine Ltd
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7319491/ https://ncbi.nlm.nih.gov/pubmed/32546029 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/imt-2020-0136 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|